FMI
VKTX icon

F/M Investments’s Viking Therapeutics VKTX Stock Holding History

F/M Investments’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-37,575
Closed -$1.51M – 413
2024
Q4 		$1.51M Sell
37,575
-10,179
-21% -$580K 0.06% 257
2024
Q3 		$3.02M Buy
47,754
+6,933
+17% +$407K 0.1% 193
2024
Q2 		$2.16M Buy
+40,821
New +$2.68M 0.08% 206

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

F/M Investments's VKTX Position: Q1 2025 in Review

F/M Investments sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 37,575 shares — an estimated $1.51M sold.

F/M Investments first reported a position in VKTX in Q2 2024 and held it in 3 quarters. The position peaked at $3.02M in Q3 2024. 373 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • F/M Investments reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • F/M Investments sold 37,575 Viking Therapeutics shares in Q1 2025, an estimated $1.51M.
  • F/M Investments first reported a position in Viking Therapeutics in Q2 2024 and held it in 3 quarters.
  • F/M Investments's Viking Therapeutics position peaked at $3.02M in Q3 2024.
  • 373 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on F/M Investments's 13F filing for Q1 2025, filed 14 May 2025.